Skip to Content
health
Client Stories

Signant Health transforms the patient experience to accelerate clinical trials

Client: Signant Health
Region: Global
Industry: Life sciences

Solving patient retention with customer-driven experience and the ServiceNow NOW platform supports rapid COVID-19 vaccine development

Client Challenge: Signant Health needed to enroll tens of thousands of patients to be part of the clinical trial for Pfizer’s COVID-19 vaccine

Solution: Signant Health transformed the patient experience using the ServiceNow NOW platform to be ready to execute one of the most difficult studies to date in four weeks, which involved managing incidents from 46,000 patients

Benefits:

  • Easily scaled to meet the ongoing demands of managing multiple studies related to vaccines and COVID-19 treatments
  • Achieved a 95 percent patient satisfaction rate with a more customer-focused experience
  • Delivered quality data while keeping patients engaged

The goal at Signant Health is to improve the lives of patients, sites, and study teams worldwide by providing simple, intuitive technology that streamlines clinical trials. Formed by a merger in 2018, Signant Health has emerged as a leader in clinical trials, one that understands the patient journey and uses its experience to create technology developed by clinicians for clinicians.

The company works closely with hospitals, patients, and pharmaceutical companies, and its solutions are being used by more than 400,000 patients involved in 700 unique clinical trials across 80 countries and six continents.

“Top pharmaceutical companies have trusted Signant Health for more than 20 years based on our advanced technology and our team of experts,” says Adina Tapalaga, Vice President of Global Support Services, Signant Health. “Companies can select individual solutions to integrate with our current system or opt for our full suite for the best quality data. We proudly staff industry-leading subject matter experts who are available to advise throughout the entire process.”